© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Voglibose came out of Japan in the late 1980s, right around the time when diabetes rates started turning into a worldwide public health headache. Researchers were on the hunt for better answers than the established oral hypoglycemics, looking for something that could bring down blood sugar spikes after meals without the baggage of severe side effects or hypoglycemia. They zeroed in on fermentation products from Streptomyces species. After years of sifting through natural compounds, Japanese chemists narrowed things down to a family of alpha-glucosidase inhibitors. Among these, Voglibose (N-(1,3-dihydroxy-2-propyl)-valiolamine) showed strong ability to delay carbohydrate absorption in the gut, earning interest first across Asia and then globally. By the mid-1990s, clinical trials had well-established its role, and regulatory approvals in countries like Japan and India opened the door to broader integration in guidelines for managing type 2 diabetes, especially for patients who struggle to control postprandial glucose.
Voglibose is recognized in hospitals and pharmacies as an oral alpha-glucosidase inhibitor, usually available as 0.2 mg or 0.3 mg tablets. The drug is recommended for adults struggling to manage their blood sugar after meals. Physicians turn to it because it slows down the absorption of glucose from complex carbs by blocking the enzymes needed for breakdown in the small intestine. Patients on a diet loaded with carbs, especially in Asian populations, have seen best results with this class of medication. Supplements and generics use a range of trade names, but the results and tolerability profiles remain consistent regardless of branding—lower post-meal glucose hikes, fewer cases of dangerous hypoglycemia compared to sulfonylureas, and support for combination therapy with metformin, sulfonylureas, or insulin when single-drug plans come up short.
Looking at Voglibose, you notice a white crystalline powder that dissolves easily in water, but struggles with organic solvents like ethanol, chloroform, or ether. Its chemical formula—C10H21NO7—shows several hydroxyl groups, hinting at strong polarity. Melting point hovers around 160 to 164°C, and its structure bears similarity to natural sugars, making it a competitive inhibitor of the enzymes that snap apart oligosaccharides. Pharmacokinetic data reveals that Voglibose’s oral bioavailability is low, since most of it does the job right there in the digestive tract before leaving the body almost untouched. That means minimal risk of interactions with drugs processed by the liver or kidneys.
Brand and generic options of Voglibose get sold in pre-scored tablets to help with precise dosing. Each pack or container needs to display the batch number, expiration date, dosage form, and clear storage conditions—typically in a dry spot away from sunlight, around room temperature. Regulatory agencies require warnings about possible digestive side effects like bloating and loose stools, which sometimes show up during the first few weeks. Labels also point out the need to use with caution in people with inflammatory bowel conditions or chronic gut ulcers, since slowing carb breakdown can worsen these underlying issues. Prescribers check liver function tests during extended use since rare cases of liver enzyme elevation have popped up in post-market studies.
The commercial process for making Voglibose blends fermentation and chemical modification. Scientists start with naturally occurring valiolamine, which is produced by cultivating specific Streptomyces strains in nutrient-rich media under controlled humidity and temperature. After extraction and purification, chemical protection of certain hydroxyl groups allows selective modification: an acylation reaction attaches the 1,3-dihydroxy-2-propyl group. After removal of the protective groups through hydrolysis, repeated recrystallization gives pharmaceutical-grade crystals with the desired purity. This method has proven dependable at industrial scale, letting companies crank out batch after batch while minimizing byproducts.
Voglibose acts as a transition-state analog, getting between alpha-glucosidase enzymes and their carb targets. In chemical tweaks, the most notable involve adjusting the valiolamine backbone or side chains to boost binding or knock back off-target activity. For related research, medicinal chemists have synthesized derivatives by swapping out the propyl side chain or altering the positioning of the hydroxy groups. These efforts turn up now and again in academic literature but rarely outperform native Voglibose in terms of selectivity or safety profile. No significant metabolism occurs, so its chemical stability inside the gut makes it a predictable player for glycemic control.
The IUPAC name can get technical—N-{4-(1,3-dihydroxyprop-2-yl)-2-(hydroxymethyl)cyclohexyl}valiolamine—but the world mostly knows it as Voglibose. Over the years, the compound has gone by names such as ADASTAV, BASEN, and Volix, depending on the country and manufacturer. People writing pharmaceutical reference books and lab catalogs list it under CAS number 83480-29-9. Chemists building research libraries usually keep tabs on it under all these names to avoid missing vital papers or patents.
Handling Voglibose in manufacturing or pharmacy settings follows good manufacturing practices, with gloves and ventilated storage to guard against dust inhalation or accidental spills. While the substance itself shows low acute toxicity, repeated occupational exposure without protective measures can irritate the respiratory tract. Regulatory bodies like the FDA and EMA stress quality controls such as batch testing, impurity profiling, and shelf-life verification. Each facility keeps written protocols for spill handling, waste disposal, and regular calibration of tablet press equipment. For distribution, packaging needs to reduce risk of moisture ingress since the powder draws in water pretty easily, leading to clumping or degradation if not stored right.
Most of the Voglibose doses given out support people with type 2 diabetes or, in select cases, prediabetes after major meals. Doctors usually add it on when patients already take metformin or sulfonylureas, and still see spikes in postprandial glucose. Unlike some older drugs, it’s not known to trigger severe low blood sugars, giving physicians confidence to prescribe it for older adults or those with complex regimens. The adoption has been especially strong in countries with rice-based diets, where glucose spikes can be more dramatic. Clinical guidelines in Japan, India, and parts of Southeast Asia now feature Voglibose as a frontline strategy for tackling dietary challenges in diabetes control.
Academic teams keep digging into ways to expand Voglibose’s reach. There’s ongoing work to combine it with other hypoglycemic drugs, focusing not just on glucose, but also on cardiovascular outcomes and inflammation-related markers. Some labs are trialing new dosage forms, like extended-release tablets or fixed-dose combinations with metformin and DPP-4 inhibitors. Animal studies keep evaluating effects beyond blood sugar control, exploring whether alpha-glucosidase inhibition can change gut microbiome composition or slow the onset of diabetic complications. Research has also followed the drug’s potential to support weight management in obese patients with metabolic syndrome, showing mixed but sometimes promising signals.
Toxicology studies over several decades have found that even high doses given to lab animals cause few severe health problems. Most cases of overdose, whether accidental or intentional, end up with gastrointestinal distress—gas, abdominal cramps, or diarrhea—without long-term organ injury. Carcinogenicity testing and genotoxicity assays have come back negative. Researchers checked reproductive health and development outcomes and did not find teratogenic effects. Reports of hypersensitivity are rare and have not resulted in regulatory restrictions in any major market, but package inserts urge caution for people with known allergies to related compounds.
Voglibose has a place in diabetes care for the foreseeable future. As more people are diagnosed earlier with metabolic diseases, interest in drugs that avoid hypoglycemia or complicated titration has grown. Polypharmacy continues in modern treatment of diabetes, so well-tolerated, gut-acting agents like Voglibose fill a unique slot. Pharmaceutical research now examines how genetic differences in digestion or gut flora might shape responsiveness to alpha-glucosidase inhibitors, nudging towards personalized medicine. Developments in oral nanocarriers or co-formulations could lead to tablets that start working even faster or last longer, providing smoother glucose control. The product’s low risk of drug-drug interactions means it remains compatible with future therapies. Policy shifts in emerging economies, where carbohydrate intake stays high, should keep this compound on formularies and research roadmaps for years to come.
Seeing someone try to manage high blood sugar over a meal brings home the real-life challenge of diabetes. Voglibose steps in at a practical level — it slows down the way certain carbohydrates turn into sugar once they hit your gut. In concrete terms, it limits the blood sugar rollercoaster many face after eating. For a person living with type 2 diabetes, those sharp spikes are more than numbers; they increase the risk of nerve damage, kidney problems, and vision troubles over years.
Voglibose blocks enzymes responsible for cutting complex carbs into simple sugars inside the small intestine. The sugars, now released more slowly, avoid flooding the bloodstream all at once. Research points to lower post-meal glucose in people on voglibose, and the Japanese Diabetes Society recommends it for this very reason. Unlike some diabetes medicines, voglibose rarely leads to dangerously low blood sugar unless mixed with insulin or sulfonylureas. That tends to worry fewer patients, making them more likely to stick with their medicine.
My own family has struggled with after-meal spikes; sometimes, a normal fasting level hides these peaks. High post-meal sugars damage blood vessels, adding to heart risks over time. A 2017 study in the journal Diabetes Care found higher post-meal glucose links closely with cardiovascular issues. Voglibose mainly addresses this window, which most people underestimate.
Patients who try voglibose often describe fewer cravings after meals and a sense of steadier energy. The direct approach of working in the gut instead of the entire bloodstream reduces some side effects found with other medications. Gastrointestinal discomfort—like bloating or gas—still shows up, especially if someone eats more sugar than usual. It's a clear signal: pairing voglibose with a diet low in simple carbohydrates smooths the path.
Doctors usually suggest voglibose for adults struggling to control blood sugar after meals, even with diet and exercise. It fits best for people who cannot tolerate metformin or who want to add a targeted approach to their diabetes plan. The medicine finds a niche where others might fall short—during the specific window right after eating.
Voglibose demands respect for its timing. It works only if someone takes it before meals. The right dose and meal structure matter. Trustworthy pharmacies and detailed instructions go a long way; fake tablets and confusion about how to take it can undermine progress. Clear communication between doctors, pharmacists, and patients keeps things running smoothly.
Improving accessibility matters. Knowledge gaps common in rural areas leave diabetes patients out of the loop. More education on meal planning alongside voglibose would likely deliver bigger benefits than the medicine alone. Thoughtful public health messaging can motivate people to act before nerve pain or vision loss sets in.
Voglibose remains a tool, not a magic fix. Its best value comes through teamwork—between healthcare professionals, patients, and those who support them. Blood sugar control opens up more than just good numbers on a test. It means fewer sleepless nights worrying about long-term complications, and more freedom around the dinner table.
People living with type 2 diabetes deal with sugar spikes after eating. Voglibose aims to smooth those bumps. It belongs to a group of medications known as alpha-glucosidase inhibitors. Unlike some diabetes drugs that boost insulin, Voglibose focuses right on the gut.
I’ve spent years watching loved ones deal with diabetes. There’s a daily struggle to keep blood sugars steady and avoid sudden highs. Voglibose becomes a small daily ally in this routine. Short story: it slows down how fast the body breaks down carbs — like rice or bread — into sugars that hit the bloodstream. Normally, enzymes in our intestines chop up carbs with impressive speed. Voglibose takes the edge off that speed, so blood sugar rises more gradually and stays in a safer range after a meal.
Blood sugar spikes stress the pancreas and chase long-term problems, from nerve pain to vision loss. Families with diabetes in their history, like mine, know these struggles. Controlling those sudden jumps means feeling better in daily life and avoiding complications years down the road. Research published in journals like Diabetes Care shows that better post-meal glucose control lowers the risk of heart disease for folks with type 2 diabetes. Voglibose doesn’t work in isolation—it gets paired with healthy eating, exercise, and sometimes other medications. Still, by tackling the problem of fast carb absorption, it provides a simple and effective way to help keep those sugar levels from swinging wildly.
Like any medicine, Voglibose comes with its share of quirks. One common side effect is stomach trouble, including gas or cramps. That’s because undigested carbs head lower down the gut, giving gut bacteria more fuel to ferment. Most people find these problems get milder after a few days or weeks. Still, it pays to start at a low dose and ramp up slowly, giving your digestive system time to adjust. People with chronic digestive issues should talk with their doctor, since Voglibose can make problems worse for some. These concerns remind me how important it is to stay honest in discussing new meds with a healthcare provider. That real conversation leads to a safer, more effective experience for everyone involved.
Plenty of folks assume better control always means more medicine, or stronger medicine. My experience tells a different story. Even a small tablet like Voglibose can deliver real benefits if paired with thoughtful habits. Fruits, veggies, and exercise matter just as much. Regular blood sugar checks give instant feedback—a spike after a meal may guide a conversation about dosing or meal choices. A friend of mine uses Voglibose and swears by the improvement in his post-meal readings. He eats out less, cooks more thoughtfully, and finds that balance matters far more than chasing the lowest possible sugar number.
Voglibose offers one more option in the toolbox for managing a complex disease. Its value shows up most clearly in real lives, where steady energy means picking up grandkids or getting through work without fatigue. Watching those changes firsthand leaves no doubt—targeting the gut can bring relief and freedom to those who stick with the plan, talk openly to their doctor, and stay informed about how their body responds.
Voglibose works for people living with type 2 diabetes who struggle to keep their blood sugar controlled by diet and exercise alone. It slows down sugar absorption from the gut, blunting the post-meal blood sugar spikes that can do so much damage. People trust it to help keep readings steady. Like most medications though, taking voglibose can cause some problems, and understanding them makes a big difference in daily life.
Anyone who's used voglibose for more than a few days notices the way it can tie up the gut. Bloating, soft stools, and gassy feelings happen more than people expect. The reason is basic biology—voglibose works in the intestines, stopping enzymes from breaking down complex sugars. So more undigested carbohydrates cruise through the gut. Bacteria feast on them, churning out gas and sometimes leading to diarrhea. For most folks, this feels annoying at worst: mild cramps, extra trips to the bathroom, and embarrassment at unexpected moments. After about a week or two, the gut often gets used to the medicine, letting people get back to their routines.
Doctors hear about excessive flatulence all the time from people taking voglibose. This can be awkward both at home and at work, affecting confidence and plans. What helps most is a real conversation between doctors and patients. Cutting back on certain high-fiber foods like beans, cabbage, and carbonated drinks during the first week can help lower the gassy side effects. For me, starting with a lower dose and gradually working up meant fewer social slipups and less discomfort. Many nutrition experts recommend eating slowly during meals and chewing well to tamp down bloating.
Though problems like flatulence are common and usually mild, a tiny number of people run into more dangerous trouble. Some develop a serious allergy, shown through rashes, itching, or swelling of the lips and face. I’ve seen two such cases in a clinic over a decade—pretty rare, but both needed a quick switch to a different medication. On occasion, some folks on multi-drug regimens report blood sugar droppings dangerously low, especially if they skip meals. Symptoms like sweating, tremors, feeling weak or confused are a warning flag. Always carry a little sugar—like candy, biscuits, or glucose tablets—just in case.
Voglibose does its job on the digestive tract, so making sense of side effects means paying extra attention to what goes on in the gut. Keeping a diary to spot patterns can help figure out which foods don't play nice with the medication. Small, more frequent meals with carbohydrates spread evenly across the day let people skirt the worst bloating. If stomach upset sticks around after two or three weeks, it’s wise to tell a doctor. They can check for other causes or consider switching up treatment plans.
Balancing blood sugar sometimes means weathering a few stomach storms early in treatment. For most people, the discomfort isn’t a deal breaker. Honest conversations with healthcare providers, experimenting with meal patterns, and being prepared for rare setbacks keeps people safe and lets the benefits of voglibose shine through. The key is to know your own body, speak up about anything new or worrying, and keep treatment flexible. That’s what builds trust in managing diabetes for the long haul.
Voglibose comes up often in conversations about managing diabetes, especially for those working hard to keep blood sugar stable. This medication, drawn from the group called alpha-glucosidase inhibitors, tends to block the absorption of starch and sugar in the gut. Eating, without paying attention to when and how diabetes medicine gets taken, can play a trick on results. I’ve watched loved ones try to strike this balance — popping pills seemed meaningless whenever routine fell apart.
Doctors often say to take Voglibose just before eating, usually within 15 minutes. The fundamental idea: launch it into action in time to block sugar spikes from that meal. Taking Voglibose after eating, or on an empty stomach, usually lets the body break down carbs unchecked, wiping out the point of this drug.
Voglibose tablets generally come in low doses like 0.2 mg or 0.3 mg, and the usual pattern starts at the lowest strength, then grows only as needed. Doctors look at blood sugar logs to figure out the right dosing plan. Switching doses without medical advice can set off swings in blood sugar or worsen side effects like upset stomach, gas, or even diarrhea. My uncle once believed more pills meant better results—he just landed in the bathroom more often, not healthier. The human body doesn’t always like shortcuts.
I’ve seen how making Voglibose part of the regular meal routine matters as much as the total daily dose. Forgetting a dose before a carb-heavy meal means that food sends blood glucose right up. Skipping doses randomly or doubling up later to “catch up” doesn’t work—those peaks and crashes only bring problems. Many folks set a timer or link their medicine with meal preparation, keeping things simple and hard to miss.
Diabetes isn’t just a condition—it’s a life shift. Everything from late dinners to holiday feasts can get in the way. I have seen that honesty with doctors and dietitians helps more than guesswork. Sometimes, a change in eating habits or exercise works as well as an increase in medication. Staying on target with blood sugar checks shows if Voglibose really helps or just adds another pill to the daily lineup.
Some folks get side effects, mostly in the gut—gas, cramps, or soft stools show up, especially at first. Eating fewer simple sugars and easing up on heavy, starchy meals tends to make things smoother. Keeping an open line with the healthcare team guides what deserves worry and what’s just an adjustment. Overdosing rarely improves control, and sometimes it brings worse stomach issues.
Following the healthcare provider’s advice means more than obeying instructions—it means building a plan that’s built for real life. Medical guidelines line up with lived experience; both matter. Voglibose is one tool, not the only one, and no pill alone can replace mindful eating, regular movement, and honest feedback between patient and provider. That’s how diabetes care becomes more than a checklist—and actually fits life as it happens.
Voglibose plays a strong role in managing blood sugar for people living with type 2 diabetes. Still, it can’t be called a “fit for all” medicine. Not everyone’s body cooperates with it. Over years working with patients and talking to healthcare experts, I’ve seen common red flags that guide doctors in making safer choices. Folks with inflammatory bowel disease, ulcerative colitis, or Crohn’s disease usually run into more trouble than benefit here. Voglibose slows down carbohydrate absorption in the gut, so those with existing gut issues often feel worse with extra bloating, discomfort, or even serious digestive problems.
A lot of people forget how much their liver works behind the scenes. Voglibose doesn’t tax the liver like some medications, but medical guidelines warn against using it in people with severe liver problems. Now and then, stories appear about folks with chronic or advanced liver disease getting prescribed this drug and feeling sicker. Those who have kidney issues or are on dialysis should also have a deeper conversation with their doctor, since metabolic changes can hit harder for them. That’s not a rare scenario—chronic kidney disease shows up more in older adults who already often struggle with diabetes.
Gastrointestinal discomfort is one of the more frequent complaints I’ve heard when interviewing users and reading patient forums. Gas, diarrhea, and abdominal pain can make daily life more complicated than high blood sugar ever did. This isn’t about a rare “side effect”—it’s a pattern. For someone juggling a busy job, stubborn stomach troubles can throw everything out of rhythm. Some patients feel embarrassed to talk about digestive issues, so they stick with discomfort, not realizing it’s tied to the medicine. Honest conversations with a healthcare provider lead to better outcomes and fewer missed workdays.
Doctors tend to avoid giving Voglibose to pregnant women. Safety data is thin, and protecting a developing child always comes first. Nursing mothers don’t get much more clarity either, since research has not pinned down all the possible risks. The same goes for kids. There’s little research showing how well Voglibose works in people under 18, so most guidelines say not to use it for pediatric diabetes.
Voglibose doesn’t work the same way as insulin or sulfonylureas, so it’s rare to see dangerous lows unless other diabetes medicines are in the mix. Still, low blood sugar can sneak up when combining these treatments. Real-world cases show more lows when someone isn’t eating enough or has skipped meals. Some antibiotics, intestinal drugs, or activated charcoal can change how this medicine works, so anyone starting a new prescription should mention Voglibose to avoid bothersome or risky surprises.
Voglibose belongs in the toolkit for blood sugar control, but health decisions should feel personalized. I’ve watched thoughtful choices—regular checkups, open talks with doctors, and upfront questioning about side effects—help people avoid problems altogether. Early warning signs, like ongoing tummy pain or changes in liver tests, shouldn’t get brushed aside. With careful patient-physician collaboration, Voglibose delivers the benefit it promises without adding new problems to the mix.
| Names | |
| Preferred IUPAC name | (1S,2S,3R,4S,5S)-1-[(2R,3R,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]amino-1,2,3,4,5-pentanol |
| Other names |
Basen Volix Voglib Voglitab Vocarb |
| Pronunciation | /vɒˈɡlɪ.bəʊs/ |
| Identifiers | |
| CAS Number | 83480-29-9 |
| 3D model (JSmol) | `3D Model (JSmol) string for Voglibose:` ``` C1C(C(C(C(O1)NC2=C(C=C(C=N2)O)O)O)O)O ``` |
| Beilstein Reference | 2887357 |
| ChEBI | CHEBI:101865 |
| ChEMBL | CHEMBL1231 |
| ChemSpider | 21541102 |
| DrugBank | DB04878 |
| ECHA InfoCard | echa.infocard:100963 |
| EC Number | EC 3.2.1.- |
| Gmelin Reference | 818700 |
| KEGG | D08542 |
| MeSH | D000071246 |
| PubChem CID | 6918364 |
| RTECS number | YU0803000 |
| UNII | R0V0GZX288 |
| UN number | UN Number not assigned |
| CompTox Dashboard (EPA) | DTXSID30892460 |
| Properties | |
| Chemical formula | C10H21NO7 |
| Molar mass | 267.288 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.28 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | -2.579 |
| Vapor pressure | 4.7E-22 mmHg |
| Acidity (pKa) | 12.71 |
| Basicity (pKb) | 6.17 |
| Magnetic susceptibility (χ) | -75.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.73 |
| Dipole moment | 2.96 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 317.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1134.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3791 kJ/mol |
| Pharmacology | |
| ATC code | A10BF05 |
| Hazards | |
| Main hazards | May cause hypoglycemia, gastrointestinal disturbances (such as flatulence, diarrhea, abdominal pain), and elevated liver enzymes. |
| GHS labelling | Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Pictograms | liver-safe,renal-safe,pregnancy-consult,alcohol-warning,driving-safe |
| Signal word | Not required |
| Hazard statements | Suspected of damaging fertility or the unborn child |
| Precautionary statements | Keep out of reach of children. Use with caution in patients with gastrointestinal disorders. Not recommended for patients with severe renal impairment. Monitor blood glucose regularly. Take as prescribed by a healthcare professional. |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| LD50 (median dose) | LD50 (median dose) of Voglibose: >2000 mg/kg (oral, rat) |
| NIOSH | Not Listed |
| REL (Recommended) | 0.2 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Acarbose Miglitol Emiglitate |
